Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: A potential predictor of bone metastases and prognosticator for disease progression and survival

Urologia Internationalis

Volumn 76, Issue 1, 2006, Pages 67-71

  Thurairaja, R ^a   Iles, R K ^c   Jefferson, K ^a   McFarlane, J P ^b   Persad, R A ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Propeptide of type 1 procollagen; Prostate specific antigen

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PHOSPHOPEPTIDES; PILOT PROJECTS; PROCOLLAGEN; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 30644457048     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089738     Document Type: Article

References (20)

1. Jemal A, Thomas A, Murray T: Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. National Institute for Clinical Excellence: Guidance on Cancer Services: Improving Outcomes in Urological Cancers. London, National Institute for Clinical Excellence, 2002.
3. Carlin BI, Gerald LA: The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(suppl):2989-2994.
4. Rosenthal DI: Radiologic diagnosis of bone metastases. Cancer 1997;80(suppl):1595-1607.
5. Oesterling JE, Martin SK, Bergstralh EJ, Lowe KC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
6. Risteli L, Risteli J: Biochemical markers of bone metabolism. Ann Med 1993;25:385-393.
7. Kanis JA, McCloskey EV: Bone turnover and biochemical markers in malignancy. Cancer 1997;80(suppl):1538-1545.
8. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Mendez-Davila C, De La Pena EG: Aminoterminal propeptide of type 1 collagen and bone alkaline phosphatase in the study of bone metastasis associated with prostatic carcinoma. Scand J Clin Lab Invest 1999;59:125-132.
9. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J: Immunoassay for intact amino-terminal propeptide of human type 1 procollagen. Clin Chem 1996;42:947-954.
10. Wolff JM, Zimny M, Horchers H, Wildberger J, Buell U, Jakse G: Is prostate-specific antigen a reliable maker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33:376-381.
11. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ: Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001;88:226-230.
12. Koizumi M, Yonese J, Fukui I, Ogata E: The serum level of the amino-terminal propeptide of type 1 procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001;87:348-351.
13. De La Piedra C, Castro-Errecaborde N, Traba ML, et al: Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003;331:45-53.
14. Lentle BC, McGowan DG, Dierich H: Technetium-99m polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 1974;46:543-548.
15. Frank JA, Ling A, Patronas NJ, et al: Detection of malignant bone tumours: MR imaging vs. scintigraphy. Am J Roentgenol 1990;155:1043-1048.
16. Algra P, Bloem J, Tissing H, Falke T, Arndt J, Verboom L: Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographies 1991;11:219-232.
17. McMurtry CT, McMurtry JM: Metastatic prostate cancer: complications and treatment. J Am Geriat Soc 2003;51:1136-1142.
18. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV: Diagnostic and prognostic markers for human prostate cancer. Prostate 1997;31:264-281.
19. Rigaud J, Tiguert R, Le Normand L, et al: Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 2002;168:1423-1426.
20. Noguchi M, Kikuchi H, Ishibashi M, Noda S: Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. BJC 2003;88:195-201.